Literature DB >> 17035328

Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo.

Yung-Wei Pan1, Jarrad M Scarlett, Tammy T Luoh, Peter Kurre.   

Abstract

Human immunodeficiency virus type 1-derived lentivirus vectors bearing the vesicular stomatitis virus G (VSV-G) envelope glycoprotein demonstrate a wide host range and can stably transduce quiescent hematopoietic stem cells. In light of concerns about biosafety and potential germ line transmission, they have been used predominantly for ex vivo strategies, thought to ensure the removal of excess surface-bound particles and prevent in vivo dissemination. Studies presented here instead reveal prolonged particle adherence after ex vivo exposure, despite serial wash procedures, with subsequent transduction of secondary target cells in direct and transwell cocultures. We explored the critical parameters affecting particle retention and transfer and show that attachment to the cell surface selectively protects virus particles from serum complement-mediated inactivation. Moreover, studies with nonmyeloablated murine recipients show that transplantation of vector-exposed, washed hematopoietic cells results in systemic dissemination of functional VSV-G/lentivector particles. We demonstrate genetic marking by inadvertent transfer of vector particles and prolonged expression of transgene product in recipient tissues. Our findings have implications for biosafety, vector design, and cell biology research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035328      PMCID: PMC1797443          DOI: 10.1128/JVI.01089-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors.

Authors:  S S Case; M A Price; C T Jordan; X J Yu; L Wang; G Bauer; D L Haas; D Xu; R Stripecke; L Naldini; D B Kohn; G M Crooks
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Shuttle of lentiviral vectors via transplanted cells in vivo.

Authors:  U Blömer; I Gruh; H Witschel; A Haverich; U Martin
Journal:  Gene Ther       Date:  2005-01       Impact factor: 5.250

3.  Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.

Authors:  Caroline Cole; Jian Qiao; Timothy Kottke; Rosa Maria Diaz; Atique Ahmed; Luis Sanchez-Perez; Gregory Brunn; Jill Thompson; John Chester; Richard G Vile
Journal:  Nat Med       Date:  2005-09-18       Impact factor: 53.440

4.  Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells.

Authors:  Els Verhoeyen; Maciej Wiznerowicz; Delphine Olivier; Brigitte Izac; Didier Trono; Anne Dubart-Kupperschmitt; François-Loïc Cosset
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

5.  Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.

Authors:  Gustavo Mostoslavsky; Darrell N Kotton; Attila J Fabian; John T Gray; Jeng-Shin Lee; Richard C Mulligan
Journal:  Mol Ther       Date:  2005-06       Impact factor: 11.454

6.  Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.

Authors:  H Miyoshi; M Takahashi; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

7.  High-titer packaging cells producing recombinant retroviruses resistant to human serum.

Authors:  F L Cosset; Y Takeuchi; J L Battini; R A Weiss; M K Collins
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

8.  Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.

Authors:  B W Bigger; E K Siapati; A Mistry; S N Waddington; M S Nivsarkar; L Jacobs; R Perrett; M V Holder; C Ridler; G Kemball-Cook; R R Ali; S J Forbes; C Coutelle; N Wright; M Alison; A J Thrasher; D Bonnet; M Themis
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

9.  In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.

Authors:  Denise A Carbonaro; Xiangyang Jin; Denise Petersen; Xingchao Wang; Fred Dorey; Ki Soo Kil; Melissa Aldrich; Michael R Blackburn; Rodney E Kellems; Donald B Kohn
Journal:  Mol Ther       Date:  2006-05-02       Impact factor: 11.454

10.  Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction.

Authors:  M Pizzato; S A Marlow; E D Blair; Y Takeuchi
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

View more
  21 in total

1.  Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.

Authors:  Lee S O'Neill; Amy M Skinner; Josha A Woodward; Peter Kurre
Journal:  J Gene Med       Date:  2010-05       Impact factor: 4.565

2.  Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.

Authors:  Emily J Platt; Susan L Kozak; James P Durnin; Thomas J Hope; David Kabat
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

Review 3.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

4.  Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates.

Authors:  Olivier Menzel; Jacques Birraux; Barbara E Wildhaber; Caty Jond; Françoise Lasne; Walid Habre; Didier Trono; Tuan H Nguyen; Christophe Chardot
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

5.  HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Authors:  Michael A Moso; Jenny L Anderson; Samantha Adikari; Lachlan R Gray; Georges Khoury; Judy J Chang; Jonathan C Jacobson; Anne M Ellett; Wan-Jung Cheng; Suha Saleh; John J Zaunders; Damian F J Purcell; Paul U Cameron; Melissa J Churchill; Sharon R Lewin; Hao K Lu
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

6.  Viral Vector Biosafety in Laboratory Animal Research.

Authors:  Dalis E Collins; Jon D Reuter; Howard G Rush; Jason S Villano
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

Review 7.  Biosafety features of lentiviral vectors.

Authors:  Axel Schambach; Daniela Zychlinski; Birgitta Ehrnstroem; Christopher Baum
Journal:  Hum Gene Ther       Date:  2013-02       Impact factor: 5.695

Review 8.  Virus cell-to-cell transmission.

Authors:  Walther Mothes; Nathan M Sherer; Jing Jin; Peng Zhong
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

9.  Cellular microvesicle pathways can be targeted to transfer genetic information between non-immune cells.

Authors:  Amy M Skinner; S Lee O'Neill; Peter Kurre
Journal:  PLoS One       Date:  2009-07-13       Impact factor: 3.240

Review 10.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.